Improving patient access to novel medical technologies in Europe.
Authors
Kearney, PeterStokoe, Graham
Breithardt, Gunter
Longson, Carole
Marco, Jean
Morgan, John
Priori, Silvia
Ruether, Alric
Taylor, Rod
Hertog, Michael
Affiliation
Department of Cardiology, Cork University Hospital Wilton, Ireland., peterkearney@eircom.netIssue Date
2012-02-03T15:05:48ZMeSH
Defibrillators, Implantable/*supply & distributionEurope
Health Services Accessibility/*standards
Humans
Medical Laboratory Science/*standards
Practice Guidelines as Topic
Stents/*supply & distribution
Technology Assessment, Biomedical
Metadata
Show full item recordCitation
Eur Heart J. 2006 Apr;27(7):882-5. Epub 2006 Feb 13.Journal
European heart journalDOI
10.1093/eurheartj/ehi794PubMed ID
16476691Abstract
The European Society of Cardiology (ESC) organized a one-day workshop with clinicians, health economic experts, and health technology appraisal experts to discuss the equity of patient access to novel medical technologies in Europe. Two index technologies were considered: implantable cardioverter defibrillators (ICDs) and drug-eluting stents (DES). The use of ICDs range from 35 implants/million population in Portugal to 166 implants/million population in Germany, whereas for implants of DES (as percentage of total stents) it is lowest in Germany at 14% and high in Portugal at 65%. These differences can in part be explained by a lack of structured implementation of guidelines, the direct cost in relation to the overall healthcare budget, and to differences in procedures and models applied by Health Technology Assessment (HTA) agencies in Europe. The workshop participants concluded that physicians need to be involved in a more structured way in HTA and need to become better acquainted with its methods and terminology. Clinical guidelines should be systematically translated, explained, disseminated, updated, and adopted by cardiologists in Europe. Clinically appropriate, consistent and transparent health economic models need to be developed and high-quality international outcome and cost data should be used. A process for funding of a technology should be developed after a positive recommendation from HTA agencies. Both the ESC and the national cardiac societies should build-up health economic expertise and engage more actively in discussions with stakeholders involved in the provision of healthcare.Language
engISSN
0195-668X (Print)0195-668X (Linking)
ae974a485f413a2113503eed53cd6c53
10.1093/eurheartj/ehi794
Scopus Count
Collections
Related articles
- Health technology assessment of medical devices: What is different? An overview of three European projects.
- Authors: Schnell-Inderst P, Mayer J, Lauterberg J, Hunger T, Arvandi M, Conrads-Frank A, Nachtnebel A, Wild C, Siebert U
- Issue date: 2015
- Access to and clinical use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology Countries: 2016 Report from the European Heart Rhythm Association.
- Authors: Raatikainen MJ, Arnar DO, Merkely B, Camm AJ, Hindricks G
- Issue date: 2016 Aug
- Health technology assessment: research trends and future priorities in Europe.
- Authors: Nielsen CP, Funch TM, Kristensen FB
- Issue date: 2011 Jul
- [Quality of health care, accreditation, and health technology assessment in Croatia: role of agency for quality and accreditation in health].
- Authors: Mittermayer R, Huić M, Mestrović J
- Issue date: 2010 Dec
- National variations in the provision of cardiac services in the United Kingdom: second report of the British Cardiac Society Working Group, 2005.
- Authors: Boon N, Norell M, Hall J, Jennings K, Penny L, Wilson C, Chambers J, Weston R
- Issue date: 2006 Jul